Industry News
FDA Clears ZYN to Advertise Lower Risk Than Cigarettes in Historic First
The U.S. Food and Drug Administration has authorized 20 ZYN nicotine pouch products to be marketed with a claim that they carry less risk than cigarettes — the first time any nicotine pouch has received a modified-risk order from the agency. The decision, issued June 30, 2026, lets ZYN's maker advertise a specific health-comparison message, but it comes with strict conditions and immediate pushback from public-health groups.
What the FDA actually authorized
The orders cover 20 ZYN products made by Swedish Match USA, part of Philip Morris International. According to the FDA, the company may now market those pouches with the claim that switching completely from cigarettes to ZYN lowers a user's risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
This is a modified-risk tobacco product (MRTP) order, a designation the FDA grants only after reviewing whether a specific claim is both scientifically supported and beneficial to public health as a whole. The agency said its earlier review found ZYN pouches contain substantially lower levels of harmful constituents than cigarettes and most other smokeless tobacco.
ZYN was already the first nicotine pouch cleared for sale in the United States, back in January 2025; this new step adds the reduced-risk marketing language on top of that authorization.
Key Limitations for Consumers
- The orders expire in five years, and the FDA says it can withdraw them if youth use rises significantly or the marketing stops benefiting public health.
- The agency will monitor youth uptake and the company's compliance with marketing restrictions.
- An MRTP order is not an endorsement that the product is "safe" or "FDA-approved." Nicotine remains addictive, and the claim is strictly a comparison to smoking, not a green light for non-smokers.
The counterpoint
The decision drew sharp criticism. The American Heart Association said it was "deeply concerned," arguing the move helps the tobacco industry "perpetuate nicotine addiction." Advocates also point to the FDA's own 2025 National Youth Tobacco Survey, which found about 1.7% of middle- and high-school students — roughly 460,000 kids — reported using nicotine pouches, with more than nine in ten choosing flavored versions.
What it means for shoppers
For adult customers who already buy ZYN, little changes at the point of sale: the same products remain available, now with an FDA-reviewed basis for the "less risk than cigarettes" comparison rather than marketing spin. The order applies to 10 flavors — including Cool Mint, Wintergreen, Citrus, Coffee, and Menthol — each in 3 mg and 6 mg strengths.
It's worth keeping the claim in perspective. "Lower risk than cigarettes" is not the same as "low risk," and the authorization is aimed at adults who smoke and want a different option — not at anyone who doesn't already use nicotine. Availability and any local restrictions still depend on state and municipal law, which continues to shift for oral nicotine products.
The bottom line
The FDA has given ZYN a regulatory milestone no competitor pouch can currently match: a government-reviewed reduced-risk claim. That's a meaningful signal in a crowded pouch aisle — but it's a narrow, conditional, five-year clearance, not a safety guarantee, and the youth-use debate around it is far from settled.